Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.

Background: Imatinib mesylate has become one of the main chemotherapeutic agents currently used to treat patients with chronic myeloid leukemia (CML). Although cutaneous reactions to this drug have been documented before, this is the first time that Sweet syndrome has been reported with its use.

Observations: We report a case of Sweet syndrome secondary to the administration of imatinib to treat CML.

Association between traffic volume and health care use for asthma among residents at a U.S.-Canadian border crossing point.

Little information is available about health impacts of the North American Free Trade Agreement (NAFTA) traffic-related pollution on residents near the major traffic corridors along the U.S.-Canadian border.

Traffic volumes and respiratory health care utilization among residents in close proximity to the Peace Bridge before and after September 11, 2001.

A recent study based on data over a 10-year period (1991-2000) showed a positive association between health care utilization and prevalence of asthma, and commercial traffic at a U.S.-Canada border crossing.